Five Prime Therapeutics

Health biotech drug development oncology platform

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutics to improve the lives of patients with serious diseases. The Company currently has three product candidates in clinical development covering multiple potential indications. Cabiralizumab (FPA008) is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis and in multiple cancers in combination with Bristol-Myers Squibb Company’s PD-1 immune checkpoint inhibitor, Opdivo (nivolumab). FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that we are initially developing to treat patients with gastric (stomach) cancer and is in a Phase 1 clinical trial. FP-1039 is a fusion protein that “traps” and neutralizes cancer-promoting fibroblast growth factors, or FGFs, involved in cancer cell proliferation and new blood vessel formation that is in Phase 1b clinical development to treat patients with malignant pleural mesothelioma.

Market capitalization(2018-07-18)

$607 M

Type

Public

South San Francisco, US

Founded

2001

Size (employees)

195 (est)

Website

fiveprime.com

Five Prime Therapeutics was founded in 2001 and is headquartered in South San Francisco, US

Report incorrect company information

Key People/Management at Five Prime Therapeutics

Aron Knickerbocker

CEO

Francis Sarena

Chief Strategy Officer and Secretary

Jeff Coon

Senior Vice President, Human Resources

Helen Collins

Senior Vice President and Chief Medical Officer

Bryan Irving

Executive Vice President and Chief Scientific Officer

Nallakkan S. Arvindan

Senior Vice President, Strategic Technology Operations

Report incorrect company information

Five Prime Therapeutics Office Locations

Open Map View

Five Prime Therapeutics has an office in South San Francisco

South San Francisco, US (HQ)

2 Corporate Dr

Show all (1)

Report incorrect company information

Five Prime Therapeutics Financials and Metrics

Five Prime Therapeutics Revenue

Summary

USD
Net income (Q1, 2018)	(20.4 m)
EBIT (Q1, 2018)	(21.5 m)
Market capitalization (18-Jul-2018)	607 m
Closing share price (18-Jul-2018)	17.2
Cash (31-Mar-2018)	65.9 m

Five Prime Therapeutics's current market capitalization is $607 m.

Income Statement

Annual

USD	FY, 2013	FY, 2016	FY, 2017
General and administrative expense		35.8 b	40 m
R&D expense		94.1 b	150.9 m
Operating expense total		129.9 b	190.9 m
EBIT	(29.4 m)	(99.2 b)	(151.4 m)

Quarterly

USD	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018
General and administrative expense	4.6 m	5.2 m	8.6 b	8.1 b	9.1 b	10.5 b	9.4 m		10.5 m
R&D expense	13.3 m	24.7 m	18.3 b	22.2 b	23.9 b	33.8 b	41.7 m		43.6 m
Operating expense total	17.9 m	29.9 m	26.9 b	30.3 b	33 b	44.2 b	51.1 m	52.4 b	54 m
EBIT	(11.6 m)	(24.1 m)	(20.4 b)	(21.1 b)	(26.4 b)	(34.1 b)	(43.3 m)	(44.1 b)	(21.5 m)

show all

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Cash	8.2 m	15.3 m	150 m	7.7 m	59.8 m
Accounts Receivable
Inventories
Current Assets	77.7 m	151.3 m	528.3 m	440.1 m	311.2 m

Quarterly

USD	Q3, 2017	Q1, 2018
Cash		65.9 m
Current Assets		403 m
PP&E		30.3 m
Total Assets		436.7 m

show all

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Net Income	(28.9 m)	(37.4 m)	249.6 m	(65.7 m)	(150.2 m)
Depreciation and Amortization	1.7 m	1.6 m	1.7 m	1.7 m	2.5 m
Inventories
Accounts Payable	(209 k)	701 k	798 k	(1.6 m)	1.9 m